title: The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction.
abstract: Insulin-like growth factor-1 (IGF-1) isoforms are expressed via alternative splicing. Expression of the minor isoform IGF-1Eb [also known as mechano-growth factor (MGF)] is responsive to cell stress. Since IGF-1 isoforms differ in their E-domain regions, we are interested in determining the biological function of the MGF E-domain. To do so, a synthetic peptide analog was used to gain mechanistic insight into the actions of the E-domain. Treatment of H9c2 cells indicated a rapid cellular uptake mechanism that did not involve IGF-1 receptor activation but resulted in a nuclear localization. Peptide treatment inhibited the intrinsic apoptotic pathway in H9c2 cells subjected to cell stress with sorbitol by preventing the collapse of the mitochondrial membrane potential and inhibition of caspase-3 activation. Therefore, we administered the peptide at the time of myocardial infarction (MI) in mice. At 2 weeks post-MI cardiac function, gene expression and cell death were assayed. A significant decline in both systolic and diastolic function was evident in untreated mice based on PV loop analysis. Delivery of the E-peptide ameliorated the decline in function and resulted in significant preservation of cardiac contractility. Associated with these changes were an inhibition of pathologic hypertrophy and significantly fewer apoptotic nuclei in the viable myocardium of E-peptide-treated mice post-MI. We conclude that administration of the MGF E-domain peptide may provide a means of modulating local tissue IGF-1 autocrine/paracrine actions to preserve cardiac function, prevent cell death, and pathologic remodeling in the heart.
authors.affiliation: Center for Cardiovascular Research, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: Evangelos
authors.initials: E
authors.lastname: Mavrommatis
authors.forename: Krystyna M
authors.initials: KM
authors.lastname: Shioura
authors.forename: Tamara
authors.initials: T
authors.lastname: Los
authors.forename: Paul H
authors.initials: PH
authors.lastname: Goldspink
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D006332:Cardiomegaly / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D002460:Cell Line; D005786:Gene Expression Regulation / Q000187:drug effects; D006334:Heart Function Tests; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D009206:Myocardium / Q000473:pathology; D020033:Protein Isoforms / Q000737:chemistry / Q000378:metabolism; D017434:Protein Structure, Tertiary; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017526:Receptor, IGF Type 1 / Q000378:metabolism; D013312:Stress, Physiological / Q000187:drug effects
chemical_list: D020033:Protein Isoforms; D012333:RNA, Messenger; C523997:mechano-growth factor E, human; C527564:mechano-growth factor, mouse; C519382:mechano-growth factor, rat; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1